| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 121.6 | 137.4 | 139.8 |
| Other income | 5.1 | 3.1 | 3.9 |
| Total income | 126.6 | 140.5 | 143.7 |
| Profit before exceptional items & tax | 17.1 | 19.7 | 32.0 |
| Exceptional items | 9.1 | -2.2 | 0.0 |
| Profit before tax | 26.2 | 17.5 | 32.0 |
| Net profit | 18.6 | 12.0 | 33.3 |
| Operating margin | 20.7% | 12.5% | 22.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -44.10% |
|---|---|
| Net profit, quarter on quarter | +55.00% |
| Revenue, year on year | -13.00% |
BSE results filing, NSE: FERMENTA. Figures extracted from the filing.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹468.15
- Market cap
- ₹1,378 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 22.8×Sector 50.4×
- Promoter holding
- 64.09%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Other Announcement
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
- Value
- ₹0.20 Cr
Fermenta Biotech Partnership
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
- From
- Vellore Institute of Technology (VIT), Vellore
Fermenta Biotech Promoter Selling: ₹2.2 Cr
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
- Value
- ₹2.20 Cr
- Promoter stake change
- -0.15%
Fermenta Biotech Investor Presentation: Key Takeaways
Q1FY27 revenue flat sequentially at INR 126.2 crore. Human nutrition volume grew 18% QoQ, offsetting animal nutrition weakness. EBITDA stood at INR 22.4 crore (17.7% margin).
Fermenta Biotech Q1 FY27 Results: Net Profit ₹9.5 Cr, Down 56.0% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹121.8 Cr (-10.6% YoY) and net profit of ₹9.5 Cr (-56.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9.5 Cr · -56.0% YoY
Fermenta Biotech Earnings Call: Key Takeaways
Fermenta Biotech delivered core revenue growth of 27% YoY in FY26, driven by Vitamin D3 segments, despite headline declines from a high real-estate base in FY25.